Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the award of a new patent for its CoPrimer™ technology from South Korea's Intellectual Property Office. This adds to the company's growing portfolio of intellectual property, enhancing the protection of its molecular diagnostic tests. The CoPrimer technology underpins tests like the Logix Smart™ COVID-19 Test kit, which has sold millions globally since the pandemic's onset. Co-Diagnostics emphasizes the durability of its sales model and the significant demand from repeat customers.
Co-Diagnostics, Inc. (CODX) announced that its Logix Smart™ SARS-CoV-2 DS test has received regulatory authorization as an in vitro diagnostic (IVD) for COVID-19 detection in markets accepting CE markings. This test allows for direct saliva sampling, eliminating the need for RNA extraction, which can reduce costs and increase testing throughput. CEO Dwight Egan emphasized that this innovation could significantly aid in ongoing testing efforts, especially in areas lagging in vaccination rates. The CE marking facilitates immediate sales in the European Community and other global markets.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present virtually at the 28th International Biodetection Technologies Conference on June 18. The focus will be on point-of-care diagnostics to enhance global health and biodefense. The company's presentation at 12:30 pm ET will detail their rapid PCR testing platform aimed at normalizing daily activities during the COVID-19 pandemic. Additionally, Co-Diagnostics will showcase its products at the CARPHA Health Research Conference from June 16-19, focusing on health issues in the Caribbean region.
Co-Diagnostics, Inc. (Nasdaq: CODX) will release its first-quarter 2021 results on May 13, 2021, after the market close. A conference call and webcast will follow at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Investors can access the event on the company's website. Co-Diagnostics specializes in developing and marketing advanced molecular diagnostic tests using unique technology for detecting nucleic acid molecules, and provides licensing for specific tests across various industries.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in a webinar on April 29, 2021, featuring Dr. Heather Fehling from Clinical Reference Lab. The event will discuss PCR testing for COVID-19, highlighting non-invasive saliva tests and new applications in response to emerging strains. Co-Diagnostics’ technology is used in CRL's saliva PCR test, which boasts high sensitivity and specificity, with results typically available in 24 hours. This initiative aims to enhance testing accessibility and application in various settings.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the successful use of its Logix Smart™ COVID-19 Test Kit by Australian researchers, with results published in the Journal of Medical Microbiology. The study showed analytical sensitivity of 1010 viral copies per ml, comparable to other tests used in Western Australia. The test performed well on clinical samples, demonstrating complete concordance with the comparison assay. CEO Dwight Egan emphasized the test's robustness and the company’s commitment to affordable molecular diagnostics in remote locations.
On March 31, 2021, Co-Diagnostics, Inc. CEO Dwight Egan discussed the company's FY2020 earnings on Yahoo! Finance, emphasizing the importance of at-home and point-of-care testing in achieving normalization post-COVID-19. He highlighted the development of a new platform aimed at quick and accurate COVID-19 testing, while emphasizing that continued testing will complement vaccine distribution. The company has established a global distributor network and is expanding its diagnostic product offerings, including liquid biopsy technology, to meet future demands.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported strong financial results for Q4 and full year 2020, driven largely by its Logix Smart™ COVID-19 Test. Fourth-quarter revenue reached $27.1 million with a gross profit margin of 84.1%, leading to a net income of $12.8 million, compared to a loss of $1.7 million in Q4 2019. For the full year, revenue soared to $74.6 million, a significant increase from the previous year, with net income of $42.5 million. The company anticipates ongoing demand for COVID-19 testing in 2021 and has initiated development of new testing platforms.
Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its fourth-quarter and full-year 2020 financial results on March 25, 2021, after market close. The company will host a conference call and webcast at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan, CFO Brian Brown, and General Counsel Reed Benson. Investors can access the live event via the company's website. For those unable to attend live, a recording will be made available later.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
